Dohmen announces acquisition of BioSoteria

CEO Cynthia (Dohmen) LaConte announced today that the Dohmen Company has acquired BioSoteria, a leading provider of drug safety and risk management services to the biopharmaceutical industry.    

"As the industry paradigm shifts to one focused on the creation and approval of products for smaller, more targeted patient populations, the regulatory paradigm is also changing. Smaller patient populations mean fewer clinical trial participants and a greater commitment to post-marketing surveillance. Life Science companies need a business partner with deep knowledge and broad service capabilities in the areas of drug safety and pharmacovigilance, to help protect their promise of pharmaceutical care with the patients they serve. That's the focus of this important service expansion strategy for Dohmen," said LaConte.

LaConte points to the Food and Drug Administration Amendments Act of 2007 -- which increased the FDA's resources for more comprehensive reviews of new drugs and devices -- as another catalyst for providing expert outsourced services in this space.

"While this heightened regulatory scrutiny better protects American consumers, it also places increasing demands on life science companies. To meet clients' needs, we founded DDN Medical Affairs in 2008, expanding our service capabilities in regulatory and safety services and offering outsourced product complaint and adverse event reporting services. Then, in 2011 we acquired MedComm Solutions in Emeryville, California to expand our services to include medical communications and clinical call center capability. Now, our acquisition of BioSoteria brings new support to life science companies by helping them create both pre-and post- marketing drug safety and risk management programs, "said LaConte.

LaConte added that BioSoteria has been recognized as industry thought leaders as a result of its consulting work in drug safety educational programs, for creating the Pacific Drug Safety Summit, the largest drug safety conference in the Western US, and eLadder Safety^TM, the nation's first comprehensive online training and workshop series for pharmacovigilance and drug safety. "I'm proud to welcome BioSoteria and its industry leading team of drug safety experts to the Dohmen family of companies, said LaConte. "They're a great fit with our values and our vision of creating a more efficient, affordable and accessible healthcare system."

BioSoteria's President Sally Van Doren, Pharm D, agrees: "We're joining Dohmen because we're impressed by Dohmen's long-standing commitment to the future of healthcare, and because our proficiencies in drug safety, pharmacovigilance and risk management, combined with the varied service offerings of DDN Medical Affairs and MedComm Solutions will enable us to create a vanguard offering for the market," said Van Doren.

This latest acquisition advances Dohmen's strategy of broadening the scope of its life science service offerings. Dohmen acquired three companies nationwide in 2011: PlanIT, a health analytics firm; MedComm Solutions, a call center delivering medical information and fulfillment; and Centric Health Resources, which serves patients with rare disorders known as orphan diseases. In addition to its acquisition of BioSoteria, Dohmen plans to further expand its life science service portfolio in 2012.